Product Information
CLINDAMYCIN HCL 150 MG CAPSULE is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.1028 per EA under NDC 59762332801. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762332801
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLINDAMYCIN HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA050162FDA Approved
Before 1982
TE Code
AB
On Market Since
5/22/1970
Pharmacological Classes
Price Statistics
The NADAC for CLINDAMYCIN HCL 150 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 13.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1028 per EA |
|---|---|
| All-time high | $0.1398 (Jun 16, 2021) |
| All-time low | $0.0760 (Nov 20, 2024) |
| 52-week high | $0.1097 |
| 52-week low | $0.1028 |
| Median price | $0.1080 |
| Average price | $0.1104 |
| Largest weekly change | +26.2% (Aug 21, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the clindamycin hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
clindamycin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lincosamide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLINDAMYCIN HCL 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CLINDAMYCIN HCL 150 MG CAPSULE, manufactured by Mylan Pharmaceuticals Inc., is $0.1028 per EA (NDC 59762332801), effective Sep 30, 2026.
How has the price of CLINDAMYCIN HCL 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CLINDAMYCIN HCL 150 MG CAPSULE has risen 13.7%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CLINDAMYCIN HCL 150 MG CAPSULE?
Since Nov 28, 2013, the NADAC for CLINDAMYCIN HCL 150 MG CAPSULE has ranged from a low of $0.0760 (Nov 20, 2024) to a high of $0.1398 (Jun 16, 2021), with a median of $0.1080 per EA.
Are there cheaper alternatives to CLINDAMYCIN HCL 150 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of CLINDAMYCIN HCL 150 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CLINDAMYCIN HCL 150 MG CAPSULE?
CLINDAMYCIN HCL 150 MG CAPSULE (NDC 59762332801) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.